TSHA Share Price Performance
US$2.79
0.76 (37.44%)
66.5% undervalued intrinsic discount
US$8.32
Fair Value
Price US$2.79
AnalystConsensusTarget US$8.32
Fair ValueUS$8.32
Share PriceUS$2.79
66.5% undervalued intrinsic discount
TSHA Community Narratives
AN
Fair Value US$8.32 66.5% undervalued intrinsic discount
FDA Meetings And TSHA-102 Trials Will Advance Approval
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
Recent TSHA News & Updates
No updates
Taysha Gene Therapies, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 12, 2025
- Earnings per share (EPS)
- -0.40
- Gross Margin
- 100.00%
- Net Profit Margin
- -1,201.08%
- Debt/Equity Ratio
- 77.1%
Taysha Gene Therapies, Inc. Competitors
About TSHA
- Founded
- 2019
- Employees
- 73
- CEO
- WebsiteView website
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
Over the past 7 days, the market has dropped 1.2% with the Consumer Discretionary sector contributing the most to the decline. In contrast to the last week, the market is actually up 21% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading